AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28870191
Drug: Protocolized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocolized treatment (Control Group)
Trial: 22978325
Drug: Music-movement therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music-movement therapy (60 minutes, three times per week for 8 weeks)
Trial: 22101378
Drug: Oral valganciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valganciclovir (VGCV) 900 mg/day
Trial: 22101378
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir (GCV) 5 mg/kg twice daily
Trial: 2941056
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg/Codeine 30 mg (medium-dose combination)
Trial: 2941056
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ibuprofen/codeine combination
Trial: 2941056
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ibuprofen/codeine combination
Trial: 24406723
Drug: Intranasal orexin-A
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal orexin-A (435 nmol)
Trial: 16282050
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal drug therapy (glucosidorum Tripterygii totorum tablets and Yishen Juanbi Tablets)
Trial: 16282050
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine therapy (voltaren extended release tablets, methotrexate, and sulfasalazine)
Trial: 2167952
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy at 69.6 Gy
Trial: 2167952
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy at 60.0 to 64.8 Gy
Trial: 2167952
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy at 69.6 to 74.4 Gy
Trial: 2167952
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy at 79.2 Gy
Trial: 28628679
Drug: Ingenol mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingenol mebutate (IngMeb) gel at concentrations of 0.018% and 0.027%, applied once daily for 2 or 3 days
Trial: 26117164
Drug: Implicit emotion
RxNorm normalized name: Empliciti
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Implicit emotion regulation intervention via psychotherapy (specific dosage and duration not mentioned)
Trial: 21616527
Drug: Terutroban (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terutroban (30 mg per day)
Trial: 19004549
Drug: Subcutaneous Botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Botulinum toxin type A (BoNT/A) 22.5U
Trial: 17530942
Drug: T. terrestris
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T. terrestris (450 mg.d(‐1))
Trial: 15126543
Drug: Methyltestosterone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyltestosterone (2.5 mg/d) plus esterified estrogens (1.25 mg/d)
Trial: 15466635
Drug: Systemic heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic heparin treatment throughout the procedure
Trial: 7627280
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no sperm injection)
Trial: 6795461
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of vaccine (20 micrograms per dose) at 0, 1 and 6 months
Trial: 6795461
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of vaccine (20 micrograms per dose) + 3 ml of HBIG with the first dose
Trial: 6795461
Drug: HBIG together
RxNorm normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBIG together with the first and second doses of vaccine
Trial: 31112623
Drug: Vilaprisan 2
RxNorm normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan 2 mg
Trial: 28064304
Drug: Ophthalmic artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic artery branch retrograde intervention with urokinase (400,000 U) and papaverine (30 mg)
Trial: 28064304
Drug: Superselective ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superselective ophthalmic artery/selective carotid intervention with urokinase (400,000 U) and papaverine (30 mg)
Trial: 26602322
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel in combination prior to CAS
Trial: 21119312
Drug: Corticosteroid injections
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injections (intra-articular or subacromial) with local anesthetic
Trial: 31061017
Drug: liraglutide placebo
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: liraglutide placebo 3 mg/day
Trial: 26790823
Drug: Clomethiazole treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomethiazole treatment after 24 hours
Trial: 22779218
Drug: Oral-B Indicator
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-B Indicator manual toothbrush (MT)
Trial: 9133695
Drug: Radioiodine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine treatment with a standard activity of 15 mCi (555 MBq) of 131I
Trial: 9133695
Drug: Target dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target dose of 100 Gy
Trial: 9133695
Drug: Standard activity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard activity (15 mCi) with additional calculation of actual target dose
Trial: 3307900
Drug: Intravenous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lignocaine (2 mg/kg)
Trial: 26993629
Drug: Preventive cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive cognitive therapy with gradual, guided discontinuation of SSRIs under medical management (STOP)
Trial: 26993629
Drug: Preventive cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive cognitive therapy with gradual, guided discontinuation of SSRIs (STOP)
Trial: 25825421
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (40 units into each pectoralis major muscle through 4 serial injections)
Trial: 25825421
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% NaCl, 4 serial injections)
Trial: 23380314
Drug: l-5-hydroxytryptophan (l-5-HTP)
RxNorm normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-5-hydroxytryptophan (l-5-HTP)
Trial: 16169344
Drug: Rotational atherectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotational atherectomy (RA) followed by beta-radiation therapy
Trial: 16169344
Drug: Cutting balloon
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cutting balloon angioplasty (CBA) followed by beta-radiation therapy
Trial: 12848680
Drug: Imagent (perflexane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imagent (perflexane lipid microspheres) administered as an IV bolus at 0.125 mg/kg body weight
Trial: 15321322
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia with 2.0 ml hyperbaric 0.5% bupivacaine
Trial: 15321322
Drug: Epidural anaesthesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural anaesthesia with a local anaesthetic mixture (0.5% bupivacaine plain 10 ml, 2% lignocaine plain 10 ml, 0.1 ml of adrenaline 1 in 1000, and 2 ml of 8.4% sodium bicarbonate)
Trial: 1817663
Drug: Cantamega‐2000 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cantamega‐2000 (1 tablet daily at breakfast for 4 weeks)
Trial: 1817663
Drug: Polivitaminizant S
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polivitaminizant S (2 tablets daily at breakfast for 4 weeks)
Trial: 30663977
Drug: IBI305 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI305 (3 mg/kg)
Trial: 30353619
Drug: linaclotide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linaclotide 0.5 mg
Trial: 27737713
Drug: Self-management plan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management plan with a temporary quadrupling of the dose of inhaled corticosteroid (maximum of 14 days)
Trial: 27737713
Drug: Self-management plan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management plan without an increase in inhaled corticosteroid
Trial: 24588434
Drug: Low-intensity CRRT
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity CRRT (25 mL/kg/hour)
Trial: 24588434
Drug: High-intensity CRRT
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity CRRT (40 mL/kg/hour)
Trial: 20090434
Drug: Scheduled dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled dosing of acetaminophen and hydrocodone (167 mg/2.5 mg/5 mL) every 4 hours ATC (Groups B and C)
Trial: 20090434
Drug: PRN dosing
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRN dosing of acetaminophen and hydrocodone every 4 hours (Group A)
Trial: 20090434
Drug: Scheduled dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled dosing of acetaminophen and hydrocodone (167 mg/2.5 mg/5 mL)
Trial: 17526976
Drug: Nicorandil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (5 mg tid)
Trial: 17526976
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (ISMN: 20 mg bid)
Trial: 15476906
Drug: Valdecoxib 40
RxNorm normalized name: valdecoxib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib 40 mg/d
Trial: 11522870
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (12 g/day)
Trial: 8156094
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy for 3 years
Trial: 3045718
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose gentamicin therapy (n = 39)
Trial: 3045718
Drug: Seven day
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven day course of an appropriate antibiotic (n = 30)
Trial: 3045718
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose gentamicin therapy
Trial: 3045718
Drug: Seven day
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven day course of an appropriate antibiotic
Trial: 27662042
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin by jet injection (0.2 units/kg)
Trial: 27662042
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart by conventional pen
Trial: 24895108
Drug: Umeclidinium (UMEC)
RxNorm normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Umeclidinium (UMEC) 62.5 mcg QD
Trial: 24895108
Drug: Umeclidinium (UMEC)
RxNorm normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Umeclidinium (UMEC) 125 mcg QD
Trial: 24895108
Drug: Umeclidinium (UMEC)
RxNorm normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Umeclidinium (UMEC) doses ≥62.5 mcg QD
Trial: 24895108
Drug: Umeclidinium (UMEC)
RxNorm normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Umeclidinium (UMEC) BID dosing
Trial: 24895108
Drug: Umeclidinium (UMEC)
RxNorm normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Umeclidinium (UMEC) QD dosing
Trial: 23165811
Drug: Normal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal group (hemoglobin concentration 12-15 g/dl), n=42
Trial: 23165811
Drug: Anemic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anemic group (hemoglobin concentration 7-10 g/dl), n=44
Trial: 23165811
Drug: Anemic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anemic group (hemoglobin concentration 7-10 g/dl)
Trial: 18414916
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg morphine
Trial: 10378673
Drug: Constant rate
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant rate infusion of HAI FUDR (80 mg/m2/day) and i.v. 5-FU (1200 mg/m2/day) for 5 days every 3 weeks (schedule A)
Trial: 10378673
Drug: Chronotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronotherapy with sinusoidal modulation of HAI FUDR (80 mg/m2/day) and i.v. 5-FU (1200 mg/m2/day) for 5 days every 3 weeks (schedule B)
Trial: 10378673
Drug: Schedule A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule A (Constant rate infusion)
Trial: 1986037
Drug: Thiamin supplementation
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamin supplementation (10 mg daily)
Trial: 6688635
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (650 mg)
Trial: 6688635
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen elixir (650 mg)
Trial: 6688635
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen tablet (650 mg)
Trial: 6688635
Drug: Two commercially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two commercially available tablet formulations (325 mg each)
Trial: 27477485
Drug: scFOS (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scFOS (5 g d-1) for 4 weeks
Trial: 22522141
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg/day with probiotics (Enterococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Bacillus coagulans 50 million spores) at a dose of two capsules three times daily (group 1)
Trial: 22522141
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg/day with probiotics (group 1)
Trial: 17590511
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg levodopa/50 mg benserazide during endurance exercise
Trial: 17590511
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg levodopa/50 mg benserazide during rest
Trial: 16304854
Drug: Clopidogrel Lowplat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel Lowplat (drug B) 600 mg (8 tablets) given once
Trial: 16304854
Drug: Clopidogrel Plavix
RxNorm normalized name: clopidogrel Oral Tablet [Plavix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel Plavix (drug A) 600 mg (8 tablets) given once
Trial: 11943134
Drug: Erythromycin 600
RxNorm normalized name: erythromycin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 600 mg during fasting and 1 g postprandially
Trial: 9805101
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g for 5 days, then 3 g daily)
Trial: 7714978
Drug: Polyestradiol phosphate
RxNorm normalized name: POLYESTRADIOL PHOSPHATE
DrugBank: Polyestradiol phosphate (DB09369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyestradiol phosphate plus ethinylestradiol (80 mg polyestradiol phosphate by intramuscular injection every 4 weeks plus 50 micrograms ethinylestradiol 3 times daily)
Trial: 7714978
Drug: Estramustine phosphate
RxNorm normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estramustine phosphate (280 mg 2 times daily)
Trial: 7714978
Drug: Deferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred treatment (surveillance only)
Trial: 26945929
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide and albuterol delivered via the Combivent Respimat Soft Mist Inhaler (CVT-R)
Trial: 26945929
Drug: Chlorofluorocarbon-propelled Combivent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorofluorocarbon-propelled Combivent metered-dose inhaler (CVT-MDI)
Trial: 20649032
Drug: Neutral protamine
RxNorm normalized name: Neutral protamine hagedorn insulin
DrugBank: Neutral Protamine Hagedorn (NPH) insulin (DB18001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral protamine Hagedorn plus metformin
Trial: 18517112
Drug: Midazolam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1 mg kg(‐1)) and Remifentanil (0.1 microg kg(‐1) min(‐1))
Trial: 26332701
Drug: Hydrocodone‐acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone‐acetaminophen
Trial: 22151836
Drug: Bedtime neutral
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime neutral protamine Hagedorn (NPH) insulin
Trial: 11594440
Drug: Citicoline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (1 g/day)
Trial: 3195780
Drug: Change of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change of flush solution and pressure monitoring tubing every 24 hours
Trial: 3195780
Drug: Change of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change of flush solution every 24 hours and change of pressure monitoring tubing every 48 hours
Trial: 3195780
Drug: Change of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change of flush solution and pressure monitoring tubing every 48 hours
Trial: 30007054
Drug: Flurbiprofen spray
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen spray
Trial: 25953073
Drug: Fosphenytoin (FOS)
DrugBank: Fosphenytoin (DB01320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosphenytoin (FOS) 15 mg/kg phenytoin equivalent (PE) administered intravenously
Trial: 25953073
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo (PBO) administered intravenously
Trial: 21586792
Drug: Thin catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thin catheter for hysterosalpingography (HSG) during dye injection
Trial: 21586792
Drug: Standard metal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard metal cannula for hysterosalpingography (HSG) during dye injection
Trial: 10360765
Drug: ABT-431 (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-431 (5, 10, 20, 30, and 40 mg)
Trial: 7585759
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg diltiazem
Trial: 7585759
Drug: Titrated diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated diltiazem (200, 300, or 400 mg)
Trial: 2037708
Drug: theophylline 200
RxNorm normalized name: theophylline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: theophylline 200 mg every 12 hours alone
Trial: 2037708
Drug: theophylline 200
RxNorm normalized name: theophylline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: theophylline 200 mg every 12 hours with mexiletine 150 mg every 8 hours
Trial: 6166800
Drug: Verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120 mg thrice daily